Article
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
International journal of radiation oncology, biology, physics - 1 Sept 2023
Peled Nir, Roisman Laila C, Levison Esther, Dudnik Julia, Chernomordikov Elena, Heching Norman, Dudnik Elizabeth, Keren-Rosenberg Shoshana, Nechushtan Hovav, Salhab Ayman, Hershkovitz Dov, Tsuriel Shlomo, Hannes Victoria, Rotem Ofer, Lazarev Irina, Lichtenberg Rachel, Granot Inbal S, Krayim Bilal, Shalata Walid, Levin Daniel, Krutman Yanay, Allen Aaron M, Blumenfeld Philip, Lavrenkov Konstantin, Kian Waleed
Abstract excerpt
PURPOSE: The treatment for unresectable, locally advanced stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiation therapy (CRT) followed by consolidation durvalumab. This study aimed to evaluate the benefit of neoadjuvant osimertinib as an alternative therapy to this approach with the aim of reducing the radiation field. METHODS AND MATERIALS: This investigation was a nonrandomized, open-label,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.